Ruxolitinib for tocilizumab-refractory severe COVID-19 infection

Br J Haematol. 2020 Aug;190(4):e198-e200. doi: 10.1111/bjh.16979. Epub 2020 Jul 26.
No abstract available

Keywords: COVID-19; immunosupression; infection; transplant.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Allografts
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Blast Crisis / blood
  • Blast Crisis / therapy
  • COVID-19 / blood
  • COVID-19 Drug Treatment*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Male
  • Nitriles
  • Pyrazoles / administration & dosage*
  • Pyrimidines
  • SARS-CoV-2*
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • tocilizumab